To include your compound in the COVID-19 Resource Center, submit it here.

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Bay Area start-up is pursuing therapies targeting biology shared by pediatric and adult cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make the former a driving force instead of an afterthought.

Incubated by Canaan, Day One Biopharmaceuticals LLC is also funded by Access Biotechnology and Atlas Venture.

On average, companies make investigational cancer therapies available to children

Read the full 700 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE